🇺🇸 FDA

Company profile · Sponsor

Oric

Oric Pharmaceuticals

ORIC · NYSE pharma SOUTH SAN FRANCISCO, CA, USA
Pipeline
12
Drugs
0
Patents
8

Quick answer

Oric (ORIC) is a pharma company. headquartered in SOUTH SAN FRANCISCO, CA, USA. listed on NYSE. NovaPharmaNews links 12 pipeline programs, 0 drugs, and 8 patents to this profile..

Company facts

Ticker ORIC
Exchange NYSE
Company type pharma
Headquarters SOUTH SAN FRANCISCO, CA, USA
SEC CIK 0001796280

Pipeline (12)

Search pipeline →

  1. Placebo, DRY EXTRACT FROM CHASTE TREE FRUITS (7-11:1), EXTRACTION SOLVENT: ETHANOL 70% (V/V)

    Oric

    Primary Dysmenorrhea

    phase 3 small molecule active

    1 trial

  2. ORIC-114

    Oric

    Solid Tumors

    phase 2 small molecule active

    1 trial

  3. ORIC-114

    Oric

    Solid Tumors

    phase 2 small molecule active

    1 trial

  4. ORIC-101

    Oric

    Solid Tumor

    phase 1 small molecule terminated

    1 trial

  5. ORIC-101

    Oric

    Healthy Volunteers

    phase 1 small molecule completed

    2 trials

  6. ORIC-101

    Oric

    Prostatic Neoplasms

    phase 1 small molecule terminated

    1 trial

  7. ORIC-114

    Oric

    Food Effect in Healthy Participants

    phase 1 small molecule completed

    1 trial

  8. ORIC-114 Dose 1 + amivantamab

    Oric

    Solid Tumors

    phase 1 small molecule active

    1 trial

  9. ORIC-533

    Oric

    Relapsed or Refractory Multiple Myeloma

    phase 1 small molecule completed

    1 trial

  10. ORIC-944

    Oric

    Metastatic Prostate Cancer

    phase 1 small molecule active

    1 trial

  11. Ph 1 Study of ORIC-944 in Patients with Metastatic Prostate Cancer.

    Oric

    Prostate cancer

    phase 1 other active

    1 trial

  12. Pharmacokinetics, pharmacodynamics, safety, and tolerability of an acetonic milk thistle extract, standardized to silymarin, in subjects with MASLD

    Oric

    chronic liver disease

    phase 1 other active

    1 trial

Patents (8)

Search patents →

  1. US 12312339

    Polo like kinase 4 inhibitors

    Expires Mon May 22 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12239729

    TRPV3 agonists for the treatment of skin conditions

    Expires Mon Feb 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12054556

    Anti-PD-L1 antibody and use thereof

    Expires Mon Aug 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12018043

    CD73 inhibitors

    Expires Mon Jun 20 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12005080

    Method for promoting proliferation of immune cells

    Expires Mon Jun 06 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11993655

    Anti-PD-L1 antibody and use thereof

    Expires Mon May 23 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11858915

    Polo like kinase 4 inhibitors

    Expires Mon Dec 28 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11807658

    CD73 inhibitors

    Expires Mon Nov 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is Oric?

Oric (ORIC) is a pharma company. headquartered in SOUTH SAN FRANCISCO, CA, USA. listed on NYSE. NovaPharmaNews links 12 pipeline programs, 0 drugs, and 8 patents to this profile..

What pipeline programs does Oric sponsor?

We track 12 ClinicalTrials.gov-linked programs for Oric, including Placebo, DRY EXTRACT FROM CHASTE TREE FRUITS (7-11:1), EXTRACTION SOLVENT: ETHANOL 70% (V/V) and 11 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Oric company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.